Cidara Therapeutics Stock Fundamentals
| CDTX Stock | USD 19.59 0.90 4.82% |
Cidara Therapeutics fundamentals help investors to digest information that contributes to Cidara Therapeutics' financial success or failures. It also enables traders to predict the movement of Cidara Stock. The fundamental analysis module provides a way to measure Cidara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cidara Therapeutics stock.
At this time, Cidara Therapeutics' Total Other Income Expense Net is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 204 K in 2024, whereas Interest Expense is likely to drop slightly above 210.4 K in 2024. Cidara | Select Account or Indicator |
Cidara Therapeutics Company Operating Margin Analysis
Cidara Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Cidara Therapeutics Operating Margin | (36.76) % |
Most of Cidara Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cidara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Cidara Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Cidara Therapeutics has an Operating Margin of -36.7583%. This is 4.78% higher than that of the Biotechnology sector and 67.2% lower than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Cidara Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cidara Therapeutics's current stock value. Our valuation model uses many indicators to compare Cidara Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cidara Therapeutics competition to find correlations between indicators driving Cidara Therapeutics's intrinsic value. More Info.Cidara Therapeutics is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Cidara Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cidara Therapeutics' earnings, one of the primary drivers of an investment's value.Cidara Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cidara Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cidara Therapeutics could also be used in its relative valuation, which is a method of valuing Cidara Therapeutics by comparing valuation metrics of similar companies.Cidara Therapeutics is currently under evaluation in operating margin category among its peers.
Cidara Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cidara Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cidara Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Cidara Fundamentals
| Return On Equity | -1.53 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (2.11) % | ||||
| Operating Margin | (36.76) % | ||||
| Current Valuation | 8.26 M | ||||
| Shares Outstanding | 7.05 M | ||||
| Shares Owned By Insiders | 4.70 % | ||||
| Shares Owned By Institutions | 51.86 % | ||||
| Number Of Shares Shorted | 64.58 K | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 2.44 X | ||||
| Revenue | 63.91 M | ||||
| Gross Profit | (11.23 M) | ||||
| EBITDA | (24.36 M) | ||||
| Net Income | (22.93 M) | ||||
| Cash And Equivalents | 53.08 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 4.88 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 1.93 X | ||||
| Book Value Per Share | (1.81) X | ||||
| Cash Flow From Operations | (22.43 M) | ||||
| Short Ratio | 3.88 X | ||||
| Earnings Per Share | (23.90) X | ||||
| Target Price | 27.33 | ||||
| Number Of Employees | 69 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 131.7 M | ||||
| Total Asset | 67.03 M | ||||
| Retained Earnings | (441.43 M) | ||||
| Working Capital | (6.56 M) | ||||
| Current Asset | 108.22 M | ||||
| Current Liabilities | 5.97 M | ||||
| Net Asset | 67.03 M |
About Cidara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cidara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cidara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cidara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 25.1 M | 15.4 M | |
| Total Revenue | 63.9 M | 67.1 M | |
| Cost Of Revenue | 1.5 M | 1.4 M | |
| Stock Based Compensation To Revenue | 0.05 | 0.05 | |
| Sales General And Administrative To Revenue | 0.29 | 0.27 | |
| Research And Ddevelopement To Revenue | 1.07 | 1.02 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 14.62 | 11.47 | |
| Ebit Per Revenue | (0.38) | (0.40) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.